Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Debt (2019 - 2024)

Seres Therapeutics' Total Debt history spans 7 years, with the latest figure at $102.5 million for Q2 2024.

  • For Q2 2024, Total Debt rose 1.74% year-over-year to $102.5 million; the TTM value through Jun 2024 reached $102.5 million, up 1.74%, while the annual FY2023 figure was $101.5 million, 100.72% up from the prior year.
  • Total Debt for Q2 2024 was $102.5 million at Seres Therapeutics, roughly flat from $102.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $102.5 million in Q2 2024 and bottomed at $16.1 million in Q3 2021.
  • The 5-year median for Total Debt is $25.0 million (2020), against an average of $52.7 million.
  • The largest annual shift saw Total Debt plummeted 35.47% in 2021 before it skyrocketed 105.3% in 2022.
  • A 5-year view of Total Debt shows it stood at $24.6 million in 2020, then grew by 0.02% to $24.6 million in 2021, then surged by 105.3% to $50.6 million in 2022, then surged by 100.72% to $101.5 million in 2023, then rose by 0.94% to $102.5 million in 2024.
  • Per Business Quant, the three most recent readings for MCRB's Total Debt are $102.5 million (Q2 2024), $102.0 million (Q1 2024), and $101.5 million (Q4 2023).